INCYTE CORPORATION (INCY) Operating Margin
- Operating margin · 12 months: Value 30.05%; Formula and calculation Operating income / revenue. Period ending 2026-03-31..
Operating margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 30.05% | Operating income / revenue. Period ending 2026-03-31. $1.61B ÷ $5.36B × 100 ≈ 30.05% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 1.61B USD | Operating Income (Loss) |
| Revenue | 5.36B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 2.13B USD | Research and Development Expense |
| Selling, general and administration | 1.38B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.61B | $5.36B | (m) | $2.13B | $1.38B | 30.05% |
| 2025-12-31 | $1.51B | $5.14B | (m) | $2.05B | $1.38B | 29.46% |
| 2025-09-30 | $1.48B | $4.81B | (m) | $1.90B | $1.31B | 30.76% |
| 2025-06-30 | $1.18B | $4.58B | (m) | $1.97B | $1.29B | 25.80% |
| 2025-03-31 | $174.64M | $4.41B | (m) | $2.61B | $1.27B | 3.96% |
| 2024-12-31 | $61.37M | $4.24B | (m) | $2.61B | $1.24B | 1.45% |
| 2024-09-30 | $-52.88M | $4.08B | (m) | $2.59B | $1.21B | -1.30% |
| 2024-06-30 | $15.74M | $3.86B | (m) | $2.39B | $1.17B | 0.41% |
| 2024-03-31 | $687.65M | $3.77B | (m) | $1.65B | $1.15B | 18.25% |
| 2023-12-31 | $620.52M | $3.70B | (m) | $1.63B | $1.16B | 16.79% |
| 2023-09-30 | $503.35M | $3.61B | (m) | $1.68B | $1.14B | 13.95% |
| 2023-06-30 | $427.02M | $3.51B | (m) | $1.69B | $1.14B | 12.15% |
| 2023-03-31 | $487.67M | $3.47B | (m) | $1.64B | $1.11B | 14.05% |
| 2022-12-31 | $579.44M | $3.39B | (m) | $1.59B | $1.00B | 17.07% |
| 2022-09-30 | $620.08M | $3.33B | (m) | $1.56B | $955.52M | 18.62% |
| 2022-06-30 | $717.12M | $3.32B | (m) | $1.51B | $879.77M | 21.60% |
| 2022-03-31 | $603.52M | $3.11B | (m) | $1.50B | $795.35M | 19.38% |
| 2021-12-31 | $585.78M | $2.99B | (m) | $1.46B | $739.56M | 19.62% |
| 2021-09-30 | $639.27M | $2.91B | (m) | $1.39B | $680.35M | 21.95% |
| 2021-06-30 | $409.19M | $2.72B | (m) | $1.49B | $610.43M | 15.04% |
| 2021-03-31 | $499.13M | $2.70B | (m) | $1.44B | $559.57M | 18.47% |
| 2020-12-31 | $-263.68M | $2.67B | (m) | $2.22B | $516.92M | -9.89% |
| 2020-09-30 | $-332.90M | $2.46B | (m) | $2.12B | $486.11M | -13.55% |
| 2020-06-30 | $-203.91M | $2.39B | (m) | $1.97B | $467.93M | -8.54% |
| 2020-03-31 | $-336.07M | $2.23B | (m) | $1.97B | $455.88M | -15.07% |
| 2019-12-31 | $402.01M | $2.16B | (m) | $1.15B | $468.71M | 18.62% |
| 2019-09-30 | $388.97M | $2.11B | (m) | $1.15B | $440.89M | 18.45% |
| 2019-06-30 | $285.78M | $2.01B | (m) | $1.16B | $434.81M | 14.25% |
| 2019-03-31 | $270.40M | $2.00B | (m) | $1.17B | $436.89M | 13.54% |
| 2018-12-31 | $129.22M | $1.88B | (m) | $1.20B | $434.41M | 6.87% |
| 2018-09-30 | $-85.52M | $1.80B | (m) | $1.34B | $423.89M | -4.76% |
| 2018-06-30 | $-101.62M | $1.73B | (m) | $1.32B | $418.64M | -5.88% |
| 2018-03-31 | $-177.60M | $1.53B | (m) | $1.22B | $400.68M | -11.57% |
| 2017-12-31 | $-243.73M | $1.54B | (m) | $1.33B | $366.41M | -15.87% |
| 2017-09-30 | $-69.07M | $1.42B | (m) | $1.04B | $364.66M | -4.87% |
| 2017-06-30 | $-61.73M | $1.31B | (m) | $914.58M | $349.17M | -4.73% |
| 2017-03-31 | $-24.34M | $1.23B | (m) | $833.01M | $325.89M | -1.99% |
| 2016-12-31 | $145.00M | $1.11B | (m) | $581.86M | $303.25M | 13.11% |
| 2016-09-30 | $168.00M | $1.02B | (m) | $536.91M | $259.63M | 16.42% |
| 2016-06-30 | $145.60M | $941.24M | (m) | $525.80M | $231.46M | 15.47% |
| 2016-03-31 | $93.63M | $857.94M | (m) | $517.97M | $216.34M | 10.91% |
| 2015-12-31 | $50.65M | $753.75M | (m) | $479.51M | $196.61M | 6.72% |
| 2015-09-30 | $-40.05M | $633.84M | (m) | $461.60M | $192.60M | -6.32% |
| 2015-06-30 | $29.99M | $644.38M | (m) | $418.06M | $184.45M | 4.65% |
| 2015-03-31 | $11.20M | $580.98M | (m) | $390.30M | $173.67M | 1.93% |
| 2014-12-31 | $-4.80M | $511.50M | (m) | $347.52M | $165.77M | -0.94% |
| 2014-09-30 | $4.68M | $484.59M | (m) | $323.82M | $155.35M | 0.97% |
| 2014-06-30 | $-78.45M | $371.57M | (m) | $306.99M | $142.35M | -21.11% |
| 2014-03-31 | $-34.94M | $373.66M | (m) | $283.26M | $124.70M | -9.35% |
| 2013-12-31 | $-16.10M | $354.95M | (m) | $260.44M | $109.98M | -4.54% |
| 2013-09-30 | $30.29M | $371.72M | (m) | $245.18M | $95.69M | 8.15% |
| 2013-06-30 | $33.34M | $347.09M | (m) | $223.56M | $89.76M | 9.61% |
| 2013-03-31 | $31.24M | $331.96M | (m) | $214.19M | $86.23M | 9.41% |
| 2012-12-31 | $1.15M | $297.06M | (m) | $210.39M | $85.36M | 0.39% |
| 2012-09-30 | $-73.25M | $212.10M | (m) | $202.50M | $82.79M | -34.53% |
| 2012-06-30 | $-105.21M | $168.39M | (m) | $196.93M | $76.65M | -62.48% |
| 2012-03-31 | $-161.55M | $98.66M | (m) | $191.38M | $68.79M | -163.74% |
| 2011-12-31 | $-143.18M | $94.45M | (m) | $178.71M | $58.22M | -151.59% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $14.05M | $169.88M | (m) | $123.88M | $32.33M | 8.27% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-139.77M | $9.27M | (m) | $119.44M | $27.58M | -1508.56% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |